Reportstack

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech

 
Repost This

Naperville, IL -- (SBWIRE) -- 03/05/2014 -- Reportstack, provider of premium market research reports announces the addition of Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech market report to its offering
The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 8,000 links to online copies of actual discovery, preclinical and clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of discovery, preclinical and clinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery, preclinical and clinical stage compounds/products.

 

Chapter 3 provides an overview of discovery, preclinical and clinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery, preclinical and clinical stage deals.

 

Chapters 5 to 7 provide a review of discovery, preclinical and clinical stage deal making since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 8 provides a detailed analysis of discovery, preclinical and clinical stage payment terms including average headline, upfront, milestone and royalty rates for discovery deals.

 

Chapter 9 provides a review of the leading discovery, preclinical and clinical stage deal by headline value.

 

Chapter 10 provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of discovery, preclinical and clinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapters 11 to 13 provides a comprehensive and detailed review of discovery, preclinical and clinical stage partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in discovery, preclinical and clinical stage partnering and deal making since 2009.

 

In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery, preclinical and clinical stage products and compounds.

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:

In-depth understanding of discovery, preclinical and clinical stage deal trends since 2009

Access to headline, upfront, milestone and royalty data

Analysis of the structure of discovery, preclinical and clinical stage agreements with numerous real life case studies

Detailed access to actual discovery, preclinical and clinical stage deals entered into by the leading fifty big pharma and big biotech companies

Insight into the terms included in a discovery, preclinical and clinical stage agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals          

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

                    

Report scope

 

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements Terms and Agreements in Pharm and Biotech is intended to provide the reader with an in-depth understanding and access to discovery, preclinical and clinical stage deal trends and structure of deals entered into by leading companies worldwide.

 

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech includes:

 

Trends in discovery, preclinical and clinical stage dealmaking in the biopharma industry since 2009

Analysis of discovery, preclinical and clinical stage deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life discovery, preclinical and clinical stage deals

Access to over 8,000 discovery, preclinical and clinical stage deals

The leading discovery, preclinical and clinical stage deals by value since 2009

Most active discovery, preclinical and clinical stage dealmakers since 2009

The leading discovery, preclinical and clinical stage partnering resources

 

In Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by:

 

Company A-Z

Headline value

Stage of development at signing

Deal type

Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and biotech report provides comprehensive access to available deals and contract documents for over 8,000 discovery, preclinical and clinical stage deals. Analyzing actual contract agreements allows assessment of the following:

 

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/151198/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###